Anti-PD1 antibody [EPR4877(2)] (ab137132)

Publishing research using ab137132? Please let us know so that we can cite the reference in this datasheet.

ab137132 has been referenced in 17 publications.

  • Zhou ZH  et al. The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer. J Cancer Res Clin Oncol N/A:N/A (2017). IHC ; Human . PubMed: 28180998
  • Ring KL  et al. Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol N/A:N/A (2017). IHC ; Human . PubMed: 28233576
  • Gao J  et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23:551-555 (2017). PubMed: 28346412
  • Qin Y  et al. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology 6:e1321187 (2017). IHC ; Human . PubMed: 28680759
  • Zheng Z  et al. Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS One 12:e0184127 (2017). PubMed: 28886065
  • Ahn H  et al. Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget 8:66178-66194 (2017). PubMed: 29029502
  • Ma K  et al. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett 14:250-256 (2017). PubMed: 28693161
  • Fan Y  et al. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther 9:6075-6082 (2016). IHC ; Human . PubMed: 27785054
  • Kim JW  et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer 19:42-52 (2016). IHC ; Human . PubMed: 25424150
  • Ji M  et al. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biol Ther N/A:0 (2016). IHC ; Human . PubMed: 26954523
  • Chen PL  et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov N/A:N/A (2016). PubMed: 27301722
  • Shi LZ  et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun 7:12335 (2016). IHC-P ; Human . PubMed: 27498556
  • Zou MX  et al. Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. Am J Transl Res 8:3274-87 (2016). IHC-P ; Human . PubMed: 27508049
  • Li Y  et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer 15:55 (2016). IHC-P ; Human . PubMed: 27552968
  • Cooper ZA  et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5:e1136044 (2016). IHC-P ; Human . PubMed: 27141370
  • Antonios JP  et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight 1:N/A (2016). PubMed: 27453950
  • Lim YJ  et al. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. Radiother Oncol 117:165-70 (2015). IHC-P ; Human . PubMed: 26235847


Sign up